P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Hui Zhu
Meta Tag
Speaker Hui Zhu
Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy
retrospective study
WCLC 2023 conference
anti-PD-L1 therapy
brain metastases
overall survival
baseline brain metastases
first-line treatment modalities
clinical implications
Powered By